CYP19A1 and breast carcinoma: Accordingly, the estrogen-dependent progression of most breast cancers could be disrupted by drugs interfering with estrogen binding to estrogen receptors (as tamoxifen), downregulating ER (as fulvestrant) or inhibiting estrogen production using aromatase inhibitors (as letrozole; LTZ) [6].